Gunther Marsche

Summary

Affiliation: Medical University of Graz
Country: Austria

Publications

  1. pmc Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo
    Gunther Marsche
    Center of Theoretical Clinical Medicine II, Medical University Graz, Universitatsplatz 4, 8010 Graz, Austria
    Circ Res 104:750-7. 2009
  2. pmc Uremia alters HDL composition and function
    Michael Holzer
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, 8010 Graz, Austria
    J Am Soc Nephrol 22:1631-41. 2011
  3. pmc Protein carbamylation renders high-density lipoprotein dysfunctional
    Michael Holzer
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, Graz, Austria
    Antioxid Redox Signal 14:2337-46. 2011
  4. pmc EP4 receptor stimulation down-regulates human eosinophil function
    Petra Luschnig-Schratl
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitaetsplatz 4, 8010 Graz, Austria
    Cell Mol Life Sci 68:3573-87. 2011
  5. ncbi Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein
    Gunther Marsche
    Medical University of Graz, Center of Molecular Medicine, Institute of Molecular Biology and Biochemistry, Harrachgasse 21, 8010 Graz, Austria
    FASEB J 21:3075-82. 2007
  6. ncbi Opposing roles of prostaglandin d2 receptors in ulcerative colitis
    Eva M Sturm
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria
    J Immunol 193:827-39. 2014
  7. pmc O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms
    Julia Kargl
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, 8010 Graz, Austria
    J Mol Med (Berl) 91:449-58. 2013
  8. doi Endothelium-derived prostaglandin I(2) controls the migration of eosinophils
    Viktoria Konya
    Institute of Experimental and Clinical Pharmacology, Medical University Graz, A 8010 Graz, Austria
    J Allergy Clin Immunol 125:1105-13. 2010

Collaborators

  • Akos Heinemann
  • Rufina Schuligoi
  • Christian Wadsack
  • Tatjana Stojakovic
  • Balazs Radnai
  • Eleonore Fröhlich
  • Petra Schratl
  • Karl Oettl
  • Eva M Sturm
  • Michael Holzer
  • Viktoria Konya
  • Rudolf Schicho
  • Angela Stančić
  • Julia Kargl
  • Petra Luschnig-Schratl
  • Irmgard Th Lippe
  • Bernhard A Peskar
  • Eckhard Beubler
  • Nerea Ferreirós
  • Christoph Hogenauer
  • Thomas R Pieber
  • Patrizia Kump
  • Heimo Wenzl
  • Wolfgang Petritsch
  • Katharina Jandl
  • Gerald P Parzmair
  • Johannes Haybaeck
  • Liisa Andersen
  • Claudia Samberger
  • Harald Koefeler
  • Ruth Birner-Gruenberger
  • Martin Gauster
  • Veronika Binder
  • Guenter Fauler
  • Sonia Philipose
  • Doris Lang-Loidolt
  • Thomas Pfeifer
  • Stefan Gattenlohner
  • Philipp Stiegler
  • Dalia El-Gamal

Detail Information

Publications8

  1. pmc Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo
    Gunther Marsche
    Center of Theoretical Clinical Medicine II, Medical University Graz, Universitatsplatz 4, 8010 Graz, Austria
    Circ Res 104:750-7. 2009
    ..Thus, depressed plasma clearance of HDL-cholesterol may contribute to the abnormal composition of HDL and the high cardiovascular risk observed in patients with chronic renal failure...
  2. pmc Uremia alters HDL composition and function
    Michael Holzer
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, 8010 Graz, Austria
    J Am Soc Nephrol 22:1631-41. 2011
    ..Assessing HDL composition and function in renal disease may help identify patients at increased risk for cardiovascular disease...
  3. pmc Protein carbamylation renders high-density lipoprotein dysfunctional
    Michael Holzer
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, Graz, Austria
    Antioxid Redox Signal 14:2337-46. 2011
    ..The present results raise the possibility that HDL carbamylation contributes to foam cell formation in atherosclerotic lesions...
  4. pmc EP4 receptor stimulation down-regulates human eosinophil function
    Petra Luschnig-Schratl
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitaetsplatz 4, 8010 Graz, Austria
    Cell Mol Life Sci 68:3573-87. 2011
    ..These data indicate that EP4 agonists might be a novel therapeutic option in eosinophilic diseases...
  5. ncbi Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein
    Gunther Marsche
    Medical University of Graz, Center of Molecular Medicine, Institute of Molecular Biology and Biochemistry, Harrachgasse 21, 8010 Graz, Austria
    FASEB J 21:3075-82. 2007
    ..We propose that sRAGE represents a physiological antagonist that interferes with scavenger receptor-mediated cholesterol accumulation and foam cell formation of macrophages...
  6. ncbi Opposing roles of prostaglandin d2 receptors in ulcerative colitis
    Eva M Sturm
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria
    J Immunol 193:827-39. 2014
    ..Although expression of CRTH2 on blood leukocytes is downregulated in UC, CRTH2 is present in colon tissue, where it may contribute to inflammation, whereas DP most likely promotes anti-inflammatory actions. ..
  7. pmc O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms
    Julia Kargl
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, 8010 Graz, Austria
    J Mol Med (Berl) 91:449-58. 2013
    ..Due to its lack of central sedation, O-1602 could be an interesting compound for the treatment of colon and possibly other cancers...
  8. doi Endothelium-derived prostaglandin I(2) controls the migration of eosinophils
    Viktoria Konya
    Institute of Experimental and Clinical Pharmacology, Medical University Graz, A 8010 Graz, Austria
    J Allergy Clin Immunol 125:1105-13. 2010
    ..Prostaglandin (PG) I(2) is the major prostanoid released by endothelial cells. Mice deficient in PGI(2) receptors (IPs) show exaggerated eosinophilic inflammation in response to allergen...